Finance Watch: Fresh Cash For Life Science Firms From venBio, Symbiotic

The biopharmaceutical industry has been through a tremendous period of company creation, and even with a drop in financings during 2022 and 2023 from record levels of funding in 2020 and 2021, the last two years have not been far off from all-time high levels of investment in drug development. That means a lot of newly created companies have put capital to work against early-stage goals and now they are looking to raise their next round of funding in a financial market that is still in recovery.

That’s where the newly formed Symbiotic Capital hopes to come in. Calling itself a first-of-its-kind global life science credit firm,...